PRME vs LCTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while PRME counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, PRME trades at N/M Forward P/E with -2584.2% operating margin (+243.9% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, PRME sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PRME Revenue | LCTX Revenue | PRME Op. Margin | LCTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -837.9% | LCTX |
| FY2019 | N/A | $0M | N/A | -1106.0% | LCTX |
| FY2020 | $10M | $0M | -17.9% | -1448.4% | PRME |
| FY2021 | N/A | $0M | N/A | -1133.6% | LCTX |
| FY2022 | N/A | $10M | N/A | -153.2% | LCTX |
| FY2023 | N/A | $10M | N/A | -276.5% | LCTX |
| FY2024 | $0M | $10M | -6787.4% | -226.1% | LCTX |
| FY2025 | $0M | $10M | -4498.1% | -251.6% | LCTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PRME | LCTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $851.8M | $212.1M | Larger Scale | PRME |
| Trailing P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | +243.9% | -61.0% | Higher Growth | PRME |
| Operating Margin (TTM) Profitability | -2584.2% | -280.3% | Higher Margin | LCTX |
| Net Profit Margin Profitability | 0.0% | 16.2% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | -207.2% | 4.3% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 36% ($3โ$6) | 4% ($1โ$2) | Stronger Trend | PRME |
| Beta / 30D Volatility Risk Regime | 2.48ฮฒ ยท 149% Vol | 1.36ฮฒ ยท 79% Vol | Lower Realized Risk | LCTX |
| Unified Institutional Score Composite Signal | 41.2 / 100 (SELL) | 58.9 / 100 (HOLD) | Higher Composite | LCTX |